Dr Hanson Yu has been recognised with the Endolift® Award of Excellence 2026, acknowledging his expertise in applying one of the most dynamic technologies in minimally invasive aesthetic medicine.
Awarded as part of the Endolift® Achievement Awards, the recognition is given to clinicians who consistently demonstrate technical precision, strong patient outcomes and sound clinical judgement in their use of Endolift®, a laser-based procedure designed to stimulate collagen, tighten tissue and address skin laxity without traditional surgery.
This award stands out for its targeted criteria. Rather than focusing broadly on technology adoption, it evaluates how effectively the treatment is delivered, including decisions around patient suitability, treatment planning and long-term results.
Endolift®, developed in Italy, has gained growing popularity across Europe and the UK as an alternative to surgical lifting. The procedure involves the use of micro-optical fibres inserted beneath the skin to deliver focused laser energy, helping to remodel tissue, reduce localised fat and enhance structural definition. Its increasing appeal lies in its ability to bridge the space between non-invasive treatments and surgical solutions.
Even with advanced technology, outcomes remain highly dependent on practitioner expertise.
Dr Hanson’s recognition reflects a wider shift within the aesthetics industry, where emphasis is moving away from device-led promotion towards clinician-driven results. In a competitive and fast-evolving market, success is increasingly defined by how treatments are applied rather than the tools themselves.
Observers of Dr Hanson’s work frequently note a careful and structured methodology. Endolift® is rarely used as a standalone option, instead forming part of a comprehensive treatment plan that considers facial anatomy, ageing progression and patient expectations over time.
This approach aligns with a broader movement in aesthetic medicine towards holistic, full-face planning and ongoing care rather than isolated interventions.
The award also reflects changing expectations among patients. As awareness of both risks and outcomes continues to grow, there is increasing demand for treatments that provide visible improvements while reducing downtime and procedural risk.
In this context, Endolift® continues to gain relevance, although its effectiveness relies on precise delivery, depth control and a strong understanding of tissue response.
For Dr Hanson, the accolade places him among a select group of practitioners recognised for advanced use of the technology. For the wider industry, it reinforces the importance of clinical discipline as the key driver of consistent, high-quality results.
